Tammy Boggiano Ayo, MSc, has a bachelor of science in radiochemistry and a master of science in biotechnology from Havana University. From 2010 to 2016, Tammy was Head of the Development Department at the Center of Molecular Immunology Antyter Plant. She is currently Process Development Director at INIM, an R&D facility at the Center of Molecular Immunology. Her international career has included positions in Spain, India, and China. Her expertise is in mammalian cell culture and fermentation, medium development, purification of mAbs, and glycoproteins.
Regulatory authorities have approved the use of recombinant monoclonal antibodies (mAbs) to treat infectious diseases1
and chronic conditions such as cancer
1Sparrow, E., M. Friede, M. Sheikh, and S. Torvaldsen. “Therapeutic Antibodies for Infectious Diseases.” Bulletin of the World Health Organization 95, no. 3 (2017):235–237. doi:10.2471/BLT.16.178061